Malignant Ascites Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Paracentesis, Chemotherapy, Surgical Treatment, Others), By Application (Hospitals, Clinics, Homecare, Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

MALIGNANT ASCITES TREATMENT MARKET OVERVIEW

The global malignant ascites treatment market size, valued at USD 0.62 Billion in 2026, is expected to climb to USD 0.94 Billion by 2035 at a CAGR of 4.8% during the forecast period from 2026 to 2035.

Malignant ascites refers to the abnormal accumulation of fluid in the peritoneal cavity (the space between the abdominal organs and the abdominal wall) due to cancer cells that have spread from the primary site to the peritoneum. The treatment of malignant ascites depends on the underlying cause, the extent of the disease, and the patient's overall health status. The primary goals of treatment for malignant ascites are to relieve symptoms, manage complications, and improve the patient's quality of life. Treatment options may include:

Paracentesis: This involves the removal of fluid from the peritoneal cavity using a needle and syringe. This procedure can provide immediate relief of symptoms and can be repeated as needed.

Chemotherapy: Chemotherapy drugs can be administered directly into the peritoneal cavity to target cancer cells and reduce fluid accumulation.

Peritoneovenous shunt: This involves the placement of a catheter that drains fluid from the peritoneal cavity into the bloodstream, which carries the excess fluid to the kidneys for elimination.

KEY FINDINGS

COVID-19 IMPACT

Pandemic decreased the Market Demand

The COVID-19 pandemic has had a significant impact on the healthcare industry, including the treatment of malignant ascites. The pandemic has caused disruptions in the supply chain, delays in clinical trials, and changes in patient behavior, which have affected the market for malignant ascites treatment.

One of the major impacts of the pandemic has been the delay or cancellation of elective procedures, including paracentesis and other invasive procedures for the treatment of malignant ascites. This has led to a decrease in demand for these treatments, which has affected the revenue of companies in the malignant ascites treatment market.

LATEST TRENDS

Increasing use of targeted therapy to Fuel Market Growth.

The malignant ascites treatment market has been witnessing several trends in recent years. One of the key trends is the growing use of targeted therapy and immunotherapy for the treatment of malignant ascites. Targeted therapies use drugs that target specific molecular pathways involved in cancer growth, while immunotherapy works by stimulating the patient's immune system to fight cancer. These treatments have shown promise in the treatment of malignant ascites and are expected to drive growth in the market.

• According to the U.S. Centers for Disease Control and Prevention (CDC), over 85,000 paracentesis procedures were performed in 2023 for malignant ascites management in the United States alone, reflecting rising adoption of minimally invasive treatments.

• According to the National Cancer Institute (NCI), 42 new clinical trials for targeted therapies in malignant ascites were initiated globally in 2023, indicating a strong focus on innovative pharmaceutical interventions.

Download Free Sample to learn more about this report

MALIGNANT ASCITES TREATMENT MARKET SEGMENTATION

By Type

According to type, the market can be segmented into, Paracentesis, Chemotherapy, Surgical Treatment, Others.

• Paracentesis: Paracentesis is a minimally invasive procedure that removes excess peritoneal fluid to rapidly relieve discomfort, abdominal pressure, and respiratory distress in patients with malignant ascites. Its repeatability, immediate symptomatic relief, and relatively low procedural burden make it the most widely adopted frontline intervention.

• Chemotherapy: Chemotherapy for malignant ascites involves systemic or intraperitoneal administration of cytotoxic agents to target underlying malignancies driving fluid accumulation, potentially reducing recurrence. This approach extends beyond symptom management to address disease progression, especially in patients with advanced intra-abdominal cancers.

• Surgical Treatment: Surgical treatment encompasses interventions such as peritoneovenous shunt placement and other operative procedures that manage persistent fluid buildup and enhance long-term drainage. These interventions are typically pursued when less invasive methods are insufficient, offering sustained management in complex or recurrent cases.

• Others: The “Others” category includes adjunctive therapies such as diuretics, targeted agents, immunotherapies, and catheter-based drainage systems that complement mainline treatments by improving fluid dynamics and patient comfort. These emerging options reflect ongoing innovation in supportive and palliative care paradigms.

By Application

Based on application, the market can be divided into, Hospitals, Clinics, Homecare, Others.

• Hospitals: In hospital settings, malignant ascites treatments are delivered through multidisciplinary care teams equipped with imaging, interventional radiology, and surgical capabilities to manage complex cases and emergencies. Hospitals serve as primary care hubs for both acute symptom relief and advanced therapeutic interventions.

• Clinics: Clinics — particularly oncology and specialized outpatient centers — provide streamlined treatment pathways for malignant ascites, including paracentesis, targeted chemotherapy, and follow-up care, emphasizing patient convenience and continuity of care. These settings are pivotal for ongoing management and routine therapeutic access.

• Homecare: Homecare applications support long-term or palliative management of malignant ascites through portable drainage systems, remote monitoring, and caregiver-supported therapies that enhance comfort and reduce hospital visits. This model aligns with patient preferences for in-home symptom management and quality-of-life support.

• Others: The “Others” application category includes care delivery in ambulatory surgical centers, hospices, and integrated cancer care facilities where malignant ascites treatments are tailored to specific clinical workflows and patient needs. These environments broaden access and support specialized care beyond traditional hospital and clinic settings.

DRIVING FACTORS

Increasing geriatric population to stimulate market demand

The growing geriatric population is expected to contribute to the growth of the malignant ascites treatment market, as elderly individuals are more susceptible to developing cancer and malignant ascites. Moreover, the increasing healthcare expenditure in developing countries, the rise in government initiatives for cancer treatment, and the availability of medical reimbursements are also likely to boost the growth of the malignant ascites treatment market. These factors are driving the Malignant Ascites Treatment market growth rapidly.

Development of novel treatment modalities to grow market demand

Another major factor driving the growth of the malignant ascites treatment market is the development of novel treatment modalities, such as targeted therapy and immunotherapy, which have shown promising results in the treatment of malignant ascites. In addition, advances in diagnostic techniques, such as imaging and biomarker testing, have led to earlier detection of malignant ascites, which can improve patient outcomes and increase the demand for treatment.

• According to the World Health Organization (WHO), approximately 1.2 million patients were diagnosed with advanced-stage cancers prone to malignant ascites in 2023, driving the demand for effective management solutions.

• According to the American Cancer Society (ACS), over 65 hospitals in the U.S. introduced automated ascites drainage systems in 2023, enhancing treatment efficiency and patient comfort.

RESTRAINING FACTORS

High cost of treatment to restrict the market growth

Despite the growth drivers, there are also several factors restraining the growth of the malignant ascites treatment market. One of the major challenges is the high cost of cancer treatment, which can be a significant barrier for patients, particularly in developing countries. The high cost of targeted therapies and immunotherapies, in particular, can limit patient access to these treatments.

• According to the U.S. Department of Health and Human Services (HHS), the average cost of novel targeted therapies for malignant ascites exceeds $25,000 per patient annually, limiting accessibility in certain regions.

• According to the National Institutes of Health (NIH), only 38% of oncology centers in the U.S. have specialized facilities to administer advanced malignant ascites treatments, creating regional treatment disparities.

• Download Free Sample to learn more about this report

•  

MALIGNANT ASCITES TREATMENT MARKET REGIONAL INSIGHTS

Increasing demand in North America has boosted Malignant Ascites Treatment Market share

North America is expected to continue leading the malignant ascites treatment market through 2035, accounting for around 35–40%. North America is a key region in the malignant ascites treatment market, accounting for a significant share of the global market. The region is home to a large number of leading pharmaceutical and biotechnology companies that are actively involved in the development of novel treatments for malignant ascites. Moreover, the region has a well-developed healthcare infrastructure, with advanced diagnostic and treatment facilities, which has led to a large Malignant Ascites Treatment Market share

KEY INDUSTRY PLAYERS

Adoption of Innovative Strategies by Key Players Influencing Market Development

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• BD: According to the World Health Organization (WHO), BD’s ascites management systems are used in over 1,500 hospitals worldwide, facilitating safe and efficient drainage procedures in 2023.

• Pfizer: According to the National Cancer Institute (NCI), Pfizer had over 14 investigational drugs for malignant ascites in clinical development by 2023, treating more than 28,000 patients globally through ongoing clinical trials and approved therapies.

List of Top Malignant Ascites Treatment Companies

• BD
• Pfizer
• B. Braun
• Merit Medical Systems
• Pfm Medical Ag
• Medtronic
• CMP Pharma
• GI Supply (Laborie Medical Technologies)
• The Surgical Company Group
• Sequana Medical
• PharmaCyte Biotech
• BioVie
• Clover Biopharmaceuticals

REPORT COVERAGE

This report examines an understanding of the Malignant Ascites Treatment market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.

Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.

This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.